KR100232341B1 - 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물 - Google Patents

류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물 Download PDF

Info

Publication number
KR100232341B1
KR100232341B1 KR1019970702392A KR19970702392A KR100232341B1 KR 100232341 B1 KR100232341 B1 KR 100232341B1 KR 1019970702392 A KR1019970702392 A KR 1019970702392A KR 19970702392 A KR19970702392 A KR 19970702392A KR 100232341 B1 KR100232341 B1 KR 100232341B1
Authority
KR
South Korea
Prior art keywords
alkyl
optionally substituted
phenyl
alkoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019970702392A
Other languages
English (en)
Korean (ko)
Other versions
KR970706270A (ko
Inventor
마크 에이 돔브로스키
케빈 코흐
안토니 다니엘 피스코피오
Original Assignee
디. 제이. 우드
화이자 인코포레이티드
스피겔 알렌 제이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디. 제이. 우드, 화이자 인코포레이티드, 스피겔 알렌 제이 filed Critical 디. 제이. 우드
Publication of KR970706270A publication Critical patent/KR970706270A/ko
Priority to KR1019990016300A priority Critical patent/KR100237528B1/ko
Priority to KR1019990016298A priority patent/KR100237527B1/ko
Application granted granted Critical
Publication of KR100232341B1 publication Critical patent/KR100232341B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
KR1019970702392A 1994-10-13 1995-05-26 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물 Expired - Fee Related KR100232341B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019990016300A KR100237528B1 (ko) 1994-10-13 1999-05-07 류코트리엔 비4 길항물질로서의 벤조피란 및 벤조-축합된 화합물
KR1019990016298A KR100237527B1 (ko) 1994-10-13 1999-05-07 류코트리엔 비4 길항물질로서의 벤조피란 및 벤조-축합된 화합물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32287694A 1994-10-13 1994-10-13
US8/322,876 1994-10-13
US08/322,876 1994-10-13
PCT/IB1995/000401 WO1996011920A1 (en) 1994-10-13 1995-05-26 Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1019990016298A Division KR100237527B1 (ko) 1994-10-13 1999-05-07 류코트리엔 비4 길항물질로서의 벤조피란 및 벤조-축합된 화합물
KR1019990016300A Division KR100237528B1 (ko) 1994-10-13 1999-05-07 류코트리엔 비4 길항물질로서의 벤조피란 및 벤조-축합된 화합물

Publications (2)

Publication Number Publication Date
KR970706270A KR970706270A (ko) 1997-11-03
KR100232341B1 true KR100232341B1 (ko) 2000-07-01

Family

ID=23256829

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702392A Expired - Fee Related KR100232341B1 (ko) 1994-10-13 1995-05-26 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물

Country Status (23)

Country Link
US (2) US6051601A (enExample)
EP (1) EP0785930A1 (enExample)
JP (1) JP2983295B2 (enExample)
KR (1) KR100232341B1 (enExample)
CN (1) CN1160399A (enExample)
AU (1) AU696890B2 (enExample)
BR (1) BR9504385A (enExample)
CA (1) CA2201742A1 (enExample)
CO (1) CO4480024A1 (enExample)
CZ (1) CZ111797A3 (enExample)
FI (1) FI971524A0 (enExample)
HU (1) HUT77515A (enExample)
IL (1) IL115529A0 (enExample)
MX (1) MX9702731A (enExample)
NO (1) NO971672L (enExample)
NZ (1) NZ285156A (enExample)
PE (1) PE10897A1 (enExample)
PL (1) PL319688A1 (enExample)
RU (1) RU2128655C1 (enExample)
TR (1) TR199501270A2 (enExample)
TW (1) TW304941B (enExample)
WO (1) WO1996011920A1 (enExample)
ZA (1) ZA958597B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096906A (en) * 1996-09-16 2000-08-01 Pfizer Inc. Processes for preparing substituted chromanol derivatives
US5817684A (en) * 1996-12-13 1998-10-06 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
IL128731A0 (en) * 1998-03-12 2000-01-31 Pfizer Prod Inc Method of preventing allograft rejection
EP0963755A3 (en) * 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
BR0206771A (pt) * 2001-01-30 2004-02-25 Pfizer Prod Inc Processos para a preparação de cidos cromanilbenzóicos
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
CA2574627A1 (en) * 2004-07-22 2006-02-02 Pharmacia Corporation Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
WO2006065686A2 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
US20080207588A1 (en) 2005-02-25 2008-08-28 Chu Daniel T W Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
JP2009536953A (ja) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｅｔｐ阻害剤としての１，２，３，４−テトラヒドロ−キノリン誘導体
CA2651817A1 (en) 2006-05-11 2007-11-22 Janssen Pharmaceutica N.V. 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
EA201100311A1 (ru) 2008-09-11 2011-10-31 Пфайзер Инк. Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
AU2010222589B2 (en) * 2009-03-11 2012-08-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
CA2864331C (en) 2012-02-14 2018-10-09 Children's Hospital Medical Center Use of small molecule inhibitors targeting the interaction between rac gtpase and p67(phox)
CN102920692A (zh) * 2012-10-25 2013-02-13 中国人民解放军第二军医大学 (e)-2-(1-羟基-4-环己酮)乙基咖啡酸酯在制备防治类风湿关节炎的药物中的应用
KR20170124602A (ko) 2015-03-13 2017-11-10 포르마 세라퓨틱스 인크. Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
WO2017095722A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
WO2017095725A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
US20190216790A1 (en) * 2016-10-13 2019-07-18 The Regents Of The University Of California Methods for Treating Pruritis
CN119700747B (zh) * 2025-02-26 2025-05-06 云南农业大学 苦杏碱醇a在制备防治骨质疏松症产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015067A1 (en) * 1992-01-23 1993-08-05 Pfizer Inc. Benzopyran and related ltb4 antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU469247A3 (ru) * 1972-01-14 1975-04-30 Майлз Лабораториз Инк (Фирма) Способ получени производных хромона
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
CA1320490C (en) * 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
CA2019335C (en) * 1989-06-27 2000-08-01 Mitoshi Konno Phenylalkan (en)oic acids
US4996230A (en) * 1990-02-16 1991-02-26 Eli Lilly And Company Leukotriene antagonists
US5073562A (en) * 1990-05-10 1991-12-17 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
US5051438A (en) * 1990-05-16 1991-09-24 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
DK0623122T3 (da) * 1992-01-23 1997-04-21 Pfizer Benzopyran og beslægtede LTB4-antagonister

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015067A1 (en) * 1992-01-23 1993-08-05 Pfizer Inc. Benzopyran and related ltb4 antagonists

Also Published As

Publication number Publication date
BR9504385A (pt) 1997-05-27
HUT77515A (hu) 1998-05-28
JP2983295B2 (ja) 1999-11-29
AU696890B2 (en) 1998-09-24
AU2416795A (en) 1996-05-06
US6133286A (en) 2000-10-17
TW304941B (enExample) 1997-05-11
KR970706270A (ko) 1997-11-03
PL319688A1 (en) 1997-08-18
PE10897A1 (es) 1997-04-21
ZA958597B (en) 1997-04-14
CN1160399A (zh) 1997-09-24
CA2201742A1 (en) 1996-04-25
CZ111797A3 (cs) 1998-07-15
EP0785930A1 (en) 1997-07-30
NO971672L (no) 1997-06-11
IL115529A0 (en) 1996-01-19
US6051601A (en) 2000-04-18
FI971524A7 (fi) 1997-04-11
FI971524A0 (fi) 1997-04-11
MX9702731A (es) 1997-06-28
NZ285156A (en) 1999-01-28
NO971672D0 (no) 1997-04-11
CO4480024A1 (es) 1997-07-09
WO1996011920A1 (en) 1996-04-25
TR199501270A2 (tr) 1996-06-21
RU2128655C1 (ru) 1999-04-10
JPH09512035A (ja) 1997-12-02

Similar Documents

Publication Publication Date Title
KR100232341B1 (ko) 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물
KR100232340B1 (ko) 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물
CA2117349C (en) Benzopyrans and related ltb4 antagonists
MXPA97002731A (en) Benzopiran and benzo compounds fused, compositions that contain them and use of mis
EP0623123B1 (en) Benzopyran and related LTB4-antagonists
HK1000245B (en) Benzopyran and related ltb4-antagonists
KR100237528B1 (ko) 류코트리엔 비4 길항물질로서의 벤조피란 및 벤조-축합된 화합물
JP2617960B2 (ja) 光学活性カルボン酸をつくる立体異性化方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20020905

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20020905

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000